Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the effectiveness of standard adjuvant treatment with CMF
chemotherapy versus treatment with weekly docetaxel in patients with high-risk breast cancer
who are 65 years of age and older or are poor candidates for anthracycline-containing
regimens. This CMF regimen has decreased dose intensity and may be slightly less active in
patients with metastatic breast cancer; however, the patient population in this trial has
tolerated more intensive CMF regimens poorly in other trials.